Our results warrant an investigation of the same anti-CDR3 mRNA vaccination design and experimentation in humanised mouse models that could be challenged with autologous T-cell lymphomas. This evidence concerns the gene TRBV20OR9-2 and T-cell non-Hodgkin lymphoma.